Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 5/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.48 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39 | 0.91 | AGTR2 (0.54) | AGTR2AGTR1GP6 | |
| SCHEMBL9328849 | 0.87 | AGTR1 (0.64) | AGTR2AGTR1 | |
| SCHEMBL10533864 | 0.87 | AGTR1 (0.49) | AGTR2AGTR1 | |
| SCHEMBL8072083 | 0.86 | GP6 (0.56) | AGTR2AGTR1GP6 | |
| SCHEMBL9558411 | 0.83 | AGTR1 (0.47) | AGTR2AGTR1 | |
| SCHEMBL7171699 | 0.83 | AGTR1 (0.57) | AGTR2AGTR1 | |
| SCHEMBL6536066 | 0.82 | AGTR1 (0.44) | AGTR2AGTR1 | |
| SCHEMBL8172767 | 0.82 | GP6 (0.63) | AGTR2AGTR1GP6 | |
| SCHEMBL9327669 | 0.81 | AGTR1 (0.57) | AGTR2AGTR1 | |
| SCHEMBL8265399 | 0.81 | AGTR2 (0.55) | AGTR2AGTR1GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | claimed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | AGTR2, AGTR1, REN | AGTR2 1/4885AGTR1 2/4885GP6 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.